Francesca Barone Sells 13,534 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 13,534 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total transaction of $97,715.48. Following the completion of the sale, the insider now directly owns 110,673 shares of the company’s stock, valued at approximately $799,059.06. This represents a 10.90 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Francesca Barone also recently made the following trade(s):

• On Wednesday, January 8th, Francesca Barone sold 13,673 shares of Candel Therapeutics stock. The shares were sold at an average price of $8.22, for a total value of $112,392.06.

Candel Therapeutics Price Performance

Shares of Candel Therapeutics stock traded down $1.03 on Friday, hitting $6.66. 1,899,373 shares of the company’s stock traded hands, compared to its average volume of 1,683,500. The firm’s 50-day moving average price is $6.58 and its two-hundred day moving average price is $6.27. The stock has a market capitalization of $216.32 million, a PE ratio of -3.85 and a beta of -1.20. Candel Therapeutics, Inc. has a one year low of $1.16 and a one year high of $14.60.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $19.00 price target (up previously from $11.00) on shares of Candel Therapeutics in a report on Wednesday, December 18th.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp grew its position in shares of Candel Therapeutics by 4.1% during the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock worth $3,410,000 after buying an additional 19,207 shares during the period. Geode Capital Management LLC raised its position in shares of Candel Therapeutics by 12.8% in the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock valued at $3,112,000 after acquiring an additional 51,111 shares during the period. HB Wealth Management LLC boosted its stake in Candel Therapeutics by 54.1% during the 4th quarter. HB Wealth Management LLC now owns 87,300 shares of the company’s stock worth $696,000 after acquiring an additional 30,642 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Candel Therapeutics during the second quarter valued at approximately $338,000. Finally, Barclays PLC increased its stake in Candel Therapeutics by 327.1% in the third quarter. Barclays PLC now owns 28,688 shares of the company’s stock valued at $199,000 after purchasing an additional 21,971 shares in the last quarter. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.